MUC16 and ovarian carcinoma: This work aims to assess the performance of CA-125 early dynamics and determine the most appropriate landmark timepoint (i.e., the timeframe required to enrich the statistical prediction models) so as to predict OS at the best future timepoint in newly diagnosed patients with advanced ovarian cancer treated with taxane- and platinum-based chemotherapy.